INFRAFRONTIER Conference 2025

28-29 April, Munich

Human Disease Modelling in Rare Diseases

The INFRAFRONTIER Conferences are back! This time with a focus on Rare Diseases, don't miss it!

28-29 April 2025

Munich, Germany

Register before 31 March

We are excited to announce that the INFRAFRONTIER Conference 2025 will take place in Munich on 28-29 April, bringing together leading experts in disease modelling to advance rare disease research.

This year’s conference will highlight the latest modelling technologies (including in silico, in vitro, and in vivo approaches) and explore how they can drive progress in clinical research for rare diseases.

About INFRAFRONTIER Conferences

The INFRAFRONTIER Conferences serve as key engagement platforms for the international mouse research community, as well as researchers working in personalised medicine, rare diseases, ageing, functional genetic variances, and cancer research.

Following the success of our previous virtual edition, which focused on the role of in vivo models in cancer research, this year’s event returns in person -to offer a unique opportunity for scientific exchange, collaboration, and networking.

Read more about our last INFRAFRONTIER Conference here.

Join us in Munich to explore the latest breakthroughs in disease modelling and their impact on rare disease research!

Confirmed Speakers

Prof Dr Dierk Niessing

about the speakerHead of the Institute of Pharmaceutical Biotechnology, Ulm University (Germany).
Principal Investigator of the Molecular Targets & Therapeutics Centre at Institute of Structural Biology at Helmholtz Centre Munich (Germany). Abstract

MD Marta Somorai

about the speakerHead of the Centre of Rare Developmental Disorders at Technical University of Munich (Germany).
Head of the Social Pediatric Centre at the kbo-Kinderzentrum at the School of Medicine and Health of Technical University of Munich (Germany). Abstract

Dr Frédérique Magdinier

about the speakerTeam Leader of Epigenetic and Nucleoskeleton Dynamics in Rare Diseases Laboratory at Marseille Medical Genetics Research Center.
Aix Marseille University-INSERM (France). Abstract

Prof Lourdes Ruiz Desviat

about the speakerProfessor of Biochemistry and Molecular Biology at Universidad Autónoma de Madrid (Spain).
Research Group Leader at Centro de Biología Molecular Severo Ochoa (UAM-CSIC) in Madrid (Spain). Abstract

Dr Theresa Hommel

about the speakerPostdoctoral Researcher at the Department of Biological Sciences and Pathobiology at Institute of in vivo and in vitro Models.
University of Veterinary Medicine Vienna (Austria). Abstract

Dr Ignacio del Castillo

about the speakerTeam Leader at Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid (Spain). Abstract

Dr Yann Herault

about the speakerDirector at Mouse Clinical Institute-CELPHEDIA, France.
Group Leader at IGBMC, Illkirch, France. Abstract

Dr Georges Arielle Peche

about the speakerRegional Manager for Paris, Tours, and Orléans at Foundation for Rare Diseases (France). Abstract

Prof Dr Reetta Hinttala

about the speakerProfessor at Faculty of Medicine, Oulu University, Oulu (Finland). Coordinator of Transgenic and Tissue Phenotyping Core Facility, Biocenter Oulu, Oulu (Finland). Biocenter Oulu, Research Unit of Clinical Medicine and Medical Research Center, Oulu University Hospital, University of Oulu, Oulu (Finland). Abstract

Prof Dr Agnes Bloch-Zupan

about the speakerProfessor in Oral Biology at the Faculty of Dentistry, Université de Strasbourg (France). Abstract

Dr Robert Harmel

about the speakerScientific Project and Industry Liaison Manager at EU OPENSCREEN. Abstract

Dr Johanna Bischof

about the speakerHead of Bio-Hub Operations at Euro-BioImaging ERIC. Abstract

MD Michele Pitaro

about the speakerConsorzio Interuniversitario “Istituto Nazionale Biostrutture e Biosistemi” (INBB), Rome (Italy).
Department of Health Sciences, University Magna Graecia Viale Europa, Catanzaro (Italy). Abstract

Dr Helene Puccio

about the speakerInstitut NeuroMyoGene, Pathophysiology and Genetics of the Neurone and Muscle (PGNM) UMR5261, INSERM U1315, Université Claude Bernard Lyon, Lyon, France.
Faculté de médecine Rockefeller, Lyon (France). Abstract

Dr Nadine Spielmann

about the speakerInstitute of Experimental Genetics (IEG) at Helmholtz Munich, Neuherberg (Germany). Abstract

Dr Sara Marcó

about the speakerCenter of Animal Biotechnology and Gene Therapy and Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma de Barcelona (Spain).
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid (Spain). Abstract

Prof Dr Eckhard Wolf

about the speakerCenter for Innovative Medical Models (CiMM), LMU Munich, Oberschleißheim (Germany). Abstract

Dr Farida Djouad

about the speakernstitute for Regenerative Medicine and Biotherapies (IRMB), CHRU – Hôpital Saint Eloi, Montpellier (France). Abstract

Dr Herman van der Putten

about the speakerResearch Head at NCL Foundation, Hamburg (Germany). Abstract

Prof Christoph Klein

about the speakerMD PhD at Dr von Hauner Children’s Hospital, Munich (Germany). Abstract

Dr Andrea Wutte

about the speakerHead of Quality Management at BBMRI-ERIC. Abstract

Dr Neil Roberts

about the speakerLecturer at Division of Cell Matrix Biology & Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health. The University of Manchester (United Kingdom). Abstract

MD Clara van Karnebeek

about the speakerProfessor & Principal Investigator at Department of Pediatrics & Human Genetics, Amsterdam University Medical Center, Amsterdam (Netherlands). Director of the Emma Center for Personalised Medicine, Amsterdam University Medical Center, Amsterdam (Netherlands). Abstract

Prof Fabio Mammano

about the speakerResearch Leader at CNR Institute of Biochemistry and Cell Biology (IBBC), Monterotondo, Rome (Italy).
Professor at University of Padova, Department of Physics and Astronomy “G. Galilei”, Padova (Italy). Abstract

CONFERENCE PROGRAMME

ABSTRACTS

What awaits you at the INFRAFRONTIER Conference 2025?

Gain insights from over 20 renowned experts in the field of rare diseases

Explore groundbreaking scientific advancements in disease modelling and preclinical research for rare diseases

Connect with the INFRAFRONTIER Consortium, Europe’s leading research infrastructure for disease modelling

…and that’s not all!

Enjoy traditional Bavarian cuisine in a lively and welcoming environment at the event dinner

Discover the monumental and vibrant city of Munich, ranked among the world’s top 20 for quality of life

Venue

Munich Marriott Hotel City West
Landsberger Str. 156
80687 Munich

Visit the venue’s site here.

Do you have questions?

We’re here to help! Reach out to us at vasb@vasensebagvre.rh

Related News

Event May 21, 2024

HMGU Hosted the Second Live CHARLIE Consortium Meeting

The second ‘live’ Charlie Consortium Meeting brought together global experts on rare diseases linked to lysine metabolism disorders at Helmholtz Munich, co-organised by the German Mouse Clinic and INFRAFRONTIER.

Scientific Publication February 8, 2024

A Link Between Autoimmune Disorders and Tooth Enamel Defects Revealed

In a groundbreaking study published in Nature, an international team of researchers, including our partners from CCP, has discovered a crucial link between autoimmune disorders and defects in tooth enamel development. This study sheds light on the poorly understood conditions of Amelogenesis Imperfecta in patients with Autoimmune Polyglandular Syndrome Type-1 (APS-1) and Celiac Disease.

Event January 31, 2024

INFRAFRONTIER Engages with Rare Disease Experts at RARE 2023 Conference in Budapest

INFRAFRONTIER recently engaged with rare disease experts at the RARE 2023 Conference in Budapest. Lively discussions at our booth focused on disease models, while sessions explored various perspectives, from early diagnosis biomarkers to palliative care. A fabulous opportunity to engage with this scientific community.

This conference is financed through INFRAPLUS project‘s funding received from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101131669.